Abstract
This double-blind, randomized, multicentcr clinical study assessed the efficacy and safety of ibopamine 100 mg t.i.d. as monotherapy vs. placebo in 52 patients with mild chronic heart failure aged over 60 years during a 12-weektreatment period. Ibopamine produced a statistically significant increase in exercise tolerance and reduction in fatigue during effort compared to placebo. A trend towards decreased requirement of concomitant diuretic therapy was noted in the ibopaminc-treated group. Ibopamine was well tolerated throughout the study. This study indicated that ibopamine is an effective and safe agent as monotherapy in the treatment of mild chronic heart failure in elderly patients.
| Original language | English |
|---|---|
| Pages (from-to) | 89-95 |
| Number of pages | 7 |
| Journal | Cardiology |
| Volume | 77 |
| DOIs | |
| Publication status | Published - 1990 |
Keywords
- Chronic
- Elderly
- heart failure
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Pharmacology (medical)
Fingerprint Dive into the research topics of 'Ibopamine in the treatment of mild chronic heart failure in elderly patients: A double-blind, placebo-controlled study'. Together they form a unique fingerprint.
Cite this
Azzolini, B., Pizzomi, C., Guffanti, E., Ronzitti, M., & Tantalo, L. (1990). Ibopamine in the treatment of mild chronic heart failure in elderly patients: A double-blind, placebo-controlled study. Cardiology, 77, 89-95. https://doi.org/10.1159/000174702